Safety and effectiveness of maxillary

[av_one_full first min_height=“ vertical_alignment=“ space=“ custom_margin=“ margin=’0px‘ padding=’0px‘ border=“ border_color=“ radius=’0px‘ background_color=“ src=“ background_position=’top left‘ background_repeat=’no-repeat‘ animation=“]

[av_textblock size=“ font_color=“ color=“]

Title: Safety and effectiveness of maxillary early loaded titanium implants with a novel nanostructured calcium-incorporated surface (Xpeed): 1-year results from a pilot multicenter randomised controlled trial.
Journal: Eur J Oral Implantol. 2012 Autumn;5(3):241-9.
Deparment of Biomaterials, the Sahlgrenska Academy at Götenburg University, Sweden.
PURPOSE: To evaluate clinical safety and effectiveness of a novel calcium-incorporated titanium implant (Xpeed, MegaGen Implant Co. Limited, Gyeongbuk, South Korea).
MATERIALS AND METHODS: Sixty patients were randomised to receive either 1 to 6 calcium-incorporated or control titanium implants in the maxilla according to a parallel group design at 2 different centres. Implants were submerged and exposed at 3 different endpoints in equal groups of 20 patients each at 12, 10 and 8 weeks, respectively. Within 2 weeks, implants were functionally loaded with provisional or definitive prostheses. Outcome measures were prosthesis failures, implant failures, any complications and peri-implant marginal bone level changes.
RESULTS: Thirty patients received 45 calcium-incorporated implants and 30 patients received 42 control titanium implants. One year after loading, no drop-outs and no prosthesis or implant failures occurred. There were no statistically significant differences between groups for complications (P = 0.61; difference in proportions = -0.27; 95% CI -0.71 to 0.18) and mean marginal bone level changes (P = 0.64; mean difference -0.04 mm; 95% CI -0.22 to 0.13).
CONCLUSIONS: Nanostructured calcium-incorporated titanium implants seem to be at least as effective and safe as conventional titanium implants.
Key words: calcium-incorporated titanium, early loading, randomised controlled trial, surface modification



MegaGen Newsletter

MegaGen Newsletter

Abonnieren Sie unseren Newsletter und bleiben Sie immer auf dem neuesten Stand.

Vielen Dank, dass Sie den Newsletter von MegaGen abonniert haben.